COVID-19 | SUBSCRIBE | FAQs

Logo Logo Logo Logo Logo
  • HOME
  • ABOUT US
    • WHO WE ARE
    • THE SAHPRA BOARD
    • EXECUTIVE MANAGEMENT
    • REGULATORY PARTNERSHIP
    • SPECIAL PROJECTS
      • BACKLOG
    • VACANCIES
  • NEWS
    • LATEST NEWS & UPDATES
    • PRESS RELEASES
    • PRESENTATIONS
    • SAHPRA TV
    • SAFETY ALERTS
    • UPCOMING EVENTS
    • WORKSHOPS AND CONFERENCES
  • HEALTH PRODUCTS
    • ORTHODOX MEDICINES
      • GUIDELNES
      • TEMPLATES
    • BIOLOGICAL PRODUCTS
      • GUIDELINES
    • COMPLEMENTARY MEDICINES
      • APPLICATION FORMS
      • COMMUNICATION TO INDUSTRY
      • GUIDELINES
      • TEMPLATES
    • MEDICAL DEVICES
      • APPLICATION FORMS
      • GUIDELINES
      • POSITION STATEMENTS
      • COMMUNICATION TO INDUSTRY
      • RELATED DOCUMENTS
    • RADIATION CONTROL
      • ACTS AND REGULATIONS
      • APPLICATION AND REPORT FORMS
      • GUIDELNES AND CODES OF PRACTICE
    • UNREGISTERED PRODUCTS
      • GUIDELINES
    • VETERINARY MEDICINES
      • GUIDELNES
  • E-SERVICES
    • ACCESS TO UNREGISTERED HEALTH PODUCTS
      • NEW AUTHORIZATIONS
      • RE-AUTHORIZATIONS
    • ADVERSE DRUG REACTION REPORTING
    • COMPLEMENTARY MEDICINES LICENSING
    • COVI-VIG REPORTING SYSTEM
    • HEALTH PRODUCT APPLICATION STATUS CHECKER
    • PRODUCT VARIATIONS PORTAL
  • PUBLICATIONS
    • ACTS AND REGULATIONS
    • ANNUAL REPORT
    • CORPORATE IDENTITY
    • GOVERNMENT GAZETTES AND REGULATIONS
    • GUIDELINES
    • FEES
    • PRESENTATIONS
    • SAHPRA PLANNING DOCUMENTS
    • TENDERS
  • CONTACT US
    • HEAD OFFICE
    • KEY CONTACTS
    • MEDIA ENQUIRIES
    • FEEDBACK AND COMPLAINTS
  • HOME
  • ABOUT US
    • WHO WE ARE
    • THE SAHPRA BOARD
    • EXECUTIVE MANAGEMENT
    • REGULATORY PARTNERSHIP
    • SPECIAL PROJECTS
      • BACKLOG
    • VACANCIES
  • NEWS
    • LATEST NEWS & UPDATES
    • PRESS RELEASES
    • PRESENTATIONS
    • SAHPRA TV
    • SAFETY ALERTS
    • UPCOMING EVENTS
    • WORKSHOPS AND CONFERENCES
  • HEALTH PRODUCTS
    • ORTHODOX MEDICINES
      • GUIDELNES
      • TEMPLATES
    • BIOLOGICAL PRODUCTS
      • GUIDELINES
    • COMPLEMENTARY MEDICINES
      • APPLICATION FORMS
      • COMMUNICATION TO INDUSTRY
      • GUIDELINES
      • TEMPLATES
    • MEDICAL DEVICES
      • APPLICATION FORMS
      • GUIDELINES
      • POSITION STATEMENTS
      • COMMUNICATION TO INDUSTRY
      • RELATED DOCUMENTS
    • RADIATION CONTROL
      • ACTS AND REGULATIONS
      • APPLICATION AND REPORT FORMS
      • GUIDELNES AND CODES OF PRACTICE
    • UNREGISTERED PRODUCTS
      • GUIDELINES
    • VETERINARY MEDICINES
      • GUIDELNES
  • E-SERVICES

    • ACCESS TO UNREGISTERED HEALTH PODUCTS

      • NEW AUTHORIZATIONS
      • RE-AUTHORIZATIONS
    • ADVERSE DRUG REACTION REPORTING
    • COMPLEMENTARY MEDICINES LICENSING
    • COVI-VIG REPORTING SYSTEM
    • HEALTH PRODUCT APPLICATION STATUS CHECKER
    • PRODUCT VARIATIONS PORTAL
  • PUBLICATIONS
    • ACTS AND REGULATIONS
    • ANNUAL REPORT
    • CORPORATE IDENTITY
    • GOVERNMENT GAZETTES AND REGULATIONS
    • GUIDELINES
    • FEES
    • PRESENTATIONS
    • SAHPRA PLANNING DOCUMENTS
    • TENDERS
  • CONTACT US
    • HEAD OFFICE
    • KEY CONTACTS
    • MEDIA ENQUIRIES
    • FEEDBACK AND COMPLAINTS

13 Dec CANNABIS Q & A

Posted at 10:15h in News & Updates by Ntokozo Msiza
Share

Download PDF

Tags:
Cannabis, CBD, Q & A, SAHPRA


Latest News
SAHPRA clarifies its stance on Ivermectin
SAHPRA AUTHORISES COVISHIELD – AN ADENOVIRUS-VECTORED VACCINE FOR THE PREVENTION OF COVID-19
SAHPRA OTC ONLINE DIRECTORY
Extension of Post Importation Testing Exemptions
Frequently Asked Questions: New Variant of SARS-CoV-2 in South Africa
INFORMATION AND GUIDANCE ON IMMUNIZATION WITH THE NEW COVID-19 VACCINES
Facebook Feed
6 days ago
SAHPRA and Rollout to President and Deputy President

Media release:

SAHPRA has approved the protocol amendment of the J&J implementation study targeted at Health Care Workers (HCW) for the inclusion of the President and the Deputy President. Whilst they are not classified as HCW, this initiative would assist greatly in encouraging vaccine uptake and reduce vaccine hesitancy.

Read more: http://bit.ly/3u2Mij4

#vaccinecovid19 #SAHPRA #presidentcyrilramaphosa
... See more

SAHPRA has approved the protocol amendment of the J&J implementation study targeted at Health Care Workers (HCW)...

View on facebook
6 days ago
SAHPRA and the SputnikV vaccine

Media release:

SAHPRA has NOT received documentation for the SputnikV vaccine developed by the Gamaleya Institute in Russia as has been reported.

Read more: https://bit.ly/3u7Hol1

#vaccinecovid19 #SAHPRA #sputniknews ... See more

SAHPRA has NOT received documentation for the SputnikV vaccine developed by the Gamaleya Institute in Russia as has been reported.

View on facebook
1 week ago
Carte Blanche Ivermectin

Carte Blanche on Ivermectin: CEO and Board Chair of SAHPRA discuss the Ivermectin issue

CEO and Board Chair of SAHPRA discuss the Ivermectin issue

View on facebook
3 weeks ago
SAHPRA clarifies its stance on Ivermectin

There is an erroneous notion that SAHPRA “buckled under pressure” as a consequence of the court action brought by, amongst others the Afriforum regarding access to Ivermectin. SAHPRA wishes to state unequivocally that this is NOT the case.

Read more: https://bit.ly/3aylVbO
... See more

There is an erroneous notion that SAHPRA “buckled under pressure” as a consequence of the court action brought by, amongst others Afriforum.

View on facebook
4 weeks ago
SAHPRA AUTHORISES COVISHIELD - AN ADENOVIRUS-VECTORED VACCINE FOR THE PREVENTION OF COVID-19 - SAHPRA

In an effort to enable and support the country’s response in fighting the #COVID19 pandemic, SAHPRA has on 22 January 2021 granted a Section 21 authorisation to the National Department of Health (South Africa) for #COVISHIED (a covid-19 vaccine manufactured by Serum Institute of India) for the prevention of #coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Read more: https://bit.ly/3t5G2a2
... See more

In an effort to enable and support the country’s response in fighting the COVID-19 pandemic, SAHPRA has on 22 January 2021 granted a Section 21 authorisation to the Department of Health for COVISHIED (a covid-19 vaccine manufactured by Serum Institute of India) for the prevention... ... See more

View on facebook
4 weeks ago
Media Briefing on Ivermectin

The South African Health Products Regulatory Authority (SAHPRA) holds a press conference to brief the media on the latest update regarding Ivermectin.

View on facebook
1 month ago
HealthTalk SABC 21Jan2021

Follow the discussion on Ivermectin on SABC 2

Follow the discussion on Ivermectin on SABC 2

View on facebook
1 month ago

Good evening

Please note that the press conference scheduled for Monday, 25 January 2021 has been canceled.

The National Department of Health (South Africa) will hold a similar press conference on Sunday, 24 January 2021. Further communication will be communicated by NDOH.

Regards,
SAHPRA
... See more

View on facebook
1 month ago
National Department of Health (South Africa)

Scientific Discussion on the new variant, 501Y.V2

Scientific Discussion on the new variant, 501Y.V2

View on facebook
1 month ago
Photos from Sahpra's post

SAHPRA would like to confirm that there has been miscommunication between our officials and Netwerk24 regarding Ivermectin. Following clarification between both parties, Netwerk24 has issued an apology (image with yellow highlights) regarding the miscommunication. The original statement from SAHPRA has the heading captioned "Ivermectin Statement". Baie dankie Netwerk24. ... See more

View on facebook
« ‹ 1 of 2 › »
Twitter Feed

SAHPRAFollow

SAHPRA
Retweet on TwitterSAHPRA Retweeted
nicd_saNICD@nicd_sa·
21 Feb

#COVID19 UPDATE: A total of 24 856 tests were conducted in the last 24 hrs, with 1 429 new cases, which represents a 6% positivity rate. A further 113 #COVID19 related deaths have been reported, bringing total fatalities to 49 053 to date. Read more here: http://ow.ly/t93G50DFWUv

Reply on Twitter 1363584055871209477Retweet on Twitter 136358405587120947723Like on Twitter 136358405587120947737Twitter 1363584055871209477
Load More...
CONTACT US

General Enquiries
For general, non-product specific enquiries only.
enquiries@sahpra.org.za

For Emergencies
For emergencies only.
emergency@sahpra.org.za

Quick Menu
  • Home
  • Covid-19 Updates
  • Safety Information
  • Payment Guideline
  • Tenders
I want to..

Apply for a vacancy

Contact SAHPRA

Know More

See Products

Read News & Updates

Newsletter Subscription

    © 2021 SAHPRA. ALL RIGHTS RESERVED

    Follow us